Two zotarolimus-eluting stent generations: A meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison

Heart

Volumn 98, Issue 22, 2012, Pages 1632-1640

  Cassese, Salvatore ^a   Ndrepepa, Gjin ^a   King, Lamin A ^a   Tada, Tomohisa ^a   Fusaro, Massimiliano ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOVOLIMUS; PACLITAXEL; PIMECROLIMUS; PROBUCOL; RAPAMYCIN; UMIROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; LOADING DRUG DOSE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT OUTCOME;

EID: 84868461078     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302519     Document Type: Article

References (40)

1. FDA. Endeavor Zotarolimus-Eluting Coronary Stent on the Over-the-Wire (OTW), Rapid Exchange (RX), or Multi Exchange II (MX2) Stent Delivery SystemsdP060033. 2008. http://www.fda.gov/MedicalDevices/ ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm074326
2. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7. (Pubitemid 44881222)
3. Udipi K, Melder RJ, Chen M, et al. The next generation Endeavor Resolute Stent: role of the BioLinx Polymer System. EuroIntervention 2007;3:137-9.
4. Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010;55:543-54.
5. Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010;375:1090-9.
6. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimuseluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010;56:1187-95.
7. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
8. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucoleluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial. Circulation 2011;124:624-32.
9. von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012;59:1350-61.
10. Palmerini T, Biondi-Zoccai G, Della Riva DD, et al. Stent thrombosis with drugeluting and bare-metal stents: evidence from a comprehensive network metaanalysis. Lancet 2012;379:1393-402.
11. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
12. Song F, Xiong T, Parekh-Bhurke S, et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 2011;343:d4909.
13. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
14. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-60. (Pubitemid 29436453)
15. Schomig A, Mehilli J, de Waha A, et al. A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:894-904.
16. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-5. (Pubitemid 32681979)
17. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91. (Pubitemid 27341818)
18. Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral Anticoagulant drugs for efficacy and safety when used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. Published Online First: 8 May 2012.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
20. Park SJ. Comparison of Resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a Randomized LONG DES IV trial. Presented At: Transcatheter Cardiovascular Therapeutics Scientific Session. November 7-11. San Francisco, CA, 2011.
21. Lee CW, Park DW, Lee SH, et al. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009;104:1370-6.
22. Byrne RA, Mehilli J, Iijima R, et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31.
23. Serruys PW, Garg S, Abizaid A, et al. A randomised comparison of novolimuseluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention 2010;6:195-205.
24. Briguori C, Airoldi F, Visconti G, et al. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv 2011;4:121-9.
25. Kang WC, Ahn T, Lee K, et al. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. EuroIntervention 2011;7:936-43.
26. Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol 2011;57:1778-83.
27. Udipi K, Chen M, Cheng P, et al. Development of a novel biocompatible polymersystem for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A 2008;85:1064-71. (Pubitemid 351717975)
28. Mehilli J, Byrne RA, Wieczorek A, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008;29:1975-82.
29. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60. (Pubitemid 40966852)
30. Guagliumi G, Ikejima H, Sirbu V, et al. Impact of drug release kinetics on vascular response to different zotarolimus-eluting stents implanted in patients with long coronary stenoses: the LongOCT study (Optical Coherence Tomography in Long Lesions). JACC Cardiovasc Interv 2011;4:778-85.
31. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42. (Pubitemid 352001347)
32. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomized multicentre trial. Circulation 2012;125:2015-26.
33. Hong MK. A new strategy for discontinuation of dual antiplatelet therapy: real safety and efficacy of 3-month dual antiplatelet therapy following zotarolimus-eluting stent implantation: RESET trial. Presented At: American College of Cardiology Scientific Session. March 24. Chicago, IL, 2012.
34. Suttorp MJ, Laarman GJ. A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. Am Heart J 2007;154:432-5. (Pubitemid 47277444)
35. Camenzind E, Wijns W, Mauri L, et al. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J 2009;158:902-9.-5.
36. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drugeluting stents: a prospective cohort study. Circulation 2012;125:1110-21.
37. Palmerini T, Kirtane AJ, Serruys PW, et al. Stent thrombosis with everolimuseluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012;5:357-64.
38. Byrne RA, Kastrati A, Tiroch K, et al. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol 2010;55:2536-43.
39. Kandzari DE, Mauri L, Popma JJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 2011;4:543-50.
40. Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-7.